MARKET

IGMS

IGMS

IGM Biosciences Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

73.43
+1.49
+2.07%
Opening 10:55 07/02 EDT
OPEN
73.30
PREV CLOSE
71.94
HIGH
74.29
LOW
72.59
VOLUME
4.48K
TURNOVER
--
52 WEEK HIGH
80.55
52 WEEK LOW
16.10
MARKET CAP
2.25B
P/E (TTM)
-41.5516
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average IGMS stock price target is 79.00 with a high estimate of 95.00 and a low estimate of 66.00.

EPS

IGMS News

More
2 Biotech Stocks That Could Soar in 2020
MotleyFool.com · 1d ago
HC Wainwright & Co. Initiates Coverage On IGM Biosciences with Buy Rating, Announces Price Target of $88
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on IGM Biosciences (NASDAQ:IGMS) with a Buy rating and announces Price Target of $88.
Benzinga · 1d ago
Stifel Maintains Buy on IGM Biosciences, Raises Price Target to $95
Stifel maintains IGM Biosciences (NASDAQ:IGMS) with a Buy and raises the price target from $67 to $95.
Benzinga · 2d ago
Hedge Funds Getting Bullish On IGM Biosciences, Inc. (IGMS)
Insider Monkey · 3d ago
The Daily Biotech Pulse: Chiasma, Heron Await FDA Decisions, DBV Restructures, 3 Biopharmas Make Wall Street Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 25)
Benzinga · 6d ago
The Daily Biotech Pulse: Merck's Wonder Cancer Drug Snags Another Approval, Decision Day For Zogenix, UniQure Out-Licenses Gene Therapy
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 24)
Benzinga · 06/25 12:26
IGM Biosciences, Inc. (NASDAQ:IGMS) Insiders Increased Their Holdings
Simply Wall St. · 06/16 11:27
IGM Biosciences to Present at the Jefferies 2020 Healthcare Conference
GlobeNewswire · 05/28 12:00

Industry

Biotechnology & Medical Research
+0.51%
Pharmaceuticals & Medical Research
+0.34%

Hot Stocks

Symbol
Price
%Change

About IGMS

IGM Biosciences Inc is a biotechnology company engaged in the development of engineered IgM antibodies for the treatment of cancer patients. It has developed IgM antibody technology platform that is particularly well suited for developing T cell engagers, receptor cross-linking agonists and targeted cytokines. The Company’s lead product candidates are IGM-2323: CD20 x CD3 and Death Receptor 5 (DR5). Its IgM platform enables to create a broad pipeline of product candidates. The Company is also conducting research and discovery programs on CD3 T cell engaging antibodies; T cell stimulating antibodies, including antibodies that target T cell stimulatory members of the TNFrSF; and antibodies that are intended to deliver IL-15 to a target to enhance cancer immune responses while limiting systemic toxicity. Its product pipelines also include CD20 x CD3, CD123 x CD3, CD38 x CD3, solid tumor target x CD3 programs, OX40 and glucocorticoid-induced TNFr-related protein (GITR).
More

Webull offers kinds of IGM Biosciences Inc stock information, including NASDAQ:IGMS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IGMS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IGMS stock methods without spending real money on the virtual paper trading platform.